Skip to main content

Table 3 Construct validity: comparison of EQ-5D and SF-6D in terms of patient subgroup differentiation and WOMAC severity level (at baseline) differentiation

From: Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain

 

EQ-5D

SF-6D

Difference

(EQ-5D vs. SF-6D)

Patient subgroups

Patients who completed the trial and had no adverse events

0.695

0.694

0.001

Patients with at least one AE

0.583

0.640

−0.057

Patients with an AE that lead to withdrawal

0.503

0.594

−0.091

Patients who discontinued therapy due to lack of efficacy

0.405

0.582

−0.176

WOMAC severity level at baseline

None to mild

0.740

0.717

0.023

Mild to moderate

0.550

0.616

−0.066

Moderate to severe

0.311

0.536

−0.225

Severe to extreme

0.180

0.461

−0.281